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OBJECTIVE — The vascular beneﬁts of statins might be attenuated by inhibition of coen-
zyme Q10 (CoQ10) synthesis. We investigated whether oral CoQ10 supplementation improves
endothelial dysfunction in statin-treated type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — In a double-blind crossover study, 23 statin-
treated type 2 diabetic patients with LDL cholesterol 2.5mmol/l and endothelial dysfunction
(brachial artery ﬂow-mediated dilatation [FMD] 5.5%) were randomized to oral CoQ10 (200
mg/day) or placebo for 12 weeks. We measured brachial artery FMD and nitrate-mediated
dilatation (NMD) by ultrasonography. Plasma F2-isoprostane and 24-h urinary 20-
hydroxyeicosatetraenoicacid(HETE)levelsweremeasuredassystemicoxidativestressmarkers.
RESULTS — Comparedwithplacebo,CoQ10supplementationincreasedbrachialarteryFMD
by 1.0  0.5% (P  0.04), but did not alter NMD (P  0.66). CoQ10 supplementation also did
not alter plasma F2-isoprostane (P  0.58) or urinary 20-HETE levels (P  0.28).
CONCLUSIONS — CoQ10 supplementation improved endothelial dysfunction in statin-
treated type 2 diabetic patients, possibly by altering local vascular oxidative stress.
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E
ndothelial dysfunction portends di-
abetic vasculopathy. Endothelial
dysfunctionreﬂectsincreasedvascu-
lar oxidative stress, whereby uncoupling
of endothelial nitric oxide synthase activ-
ity and mitochondrial oxidative phos-
phorylation impairs the bioavailability
and action of nitric oxide (1).
Statins are widely used in diabetes
management and can reduce cardiovas-
cularevents(2).However,aproportionof
statin-treated patients remain at risk of
cardiovascular disease. Statins inhibit
conversion of 3-hydroxy-3-methylglu-
taryl-CoAtomevalonate,butmaythereby
also decrease production of other inter-
mediates in the cholesterol biosynthetic
pathway, such as coenzyme Q10 (CoQ10)
(3), an important intracellular antioxi-
dant. We hypothesized that oral CoQ10




METHODS— We recruited type 2 di-
abetic patients aged 40–79 years on sta-
ble-dose statin therapy for 6 weeks.
InclusioncriteriawereserumLDLcholes-
terol 2.5 mmol/l and endothelial dys-
function, deﬁned as brachial artery ﬂow-
mediated dilatation (FMD) 5.5%.
Exclusions included use of antioxidant
supplements or other lipid-regulating
medications, GHb 8.5%, and blood
pressure 150/90 mmHg.
Eligible subjects were assigned in a
double-blind and randomized manner to
oral CoQ10 (200 mg/day) (Blackmores,
Balgowlah, Australia) or placebo for 12
weeks. After a 4-week washout, partici-
pants crossed over to the alternate treat-
ment. Brachial artery ultrasonography
was performed, and fasting blood and
24-h urine samples were collected at the
start and end of each treatment period.
The Royal Perth Hospital Ethics Commit-
tee approved the study.
The brachial artery was imaged using
a 12-MHz transducer connected to an
Acuson Aspen ultrasound system (Sie-
mens Medical Solutions, Malvern, PA),
and FMD was measured as previously de-
scribed (4). Endothelium-independent
nitrate-mediated dilatation was measured
following sublingual administration of
glyceryl trinitrate (400 g). Ultrasound
images were analyzed using semiauto-
mated edge-detection software (5).
Total cholesterol, triglycerides, and
HDL cholesterol were determined by en-
zymatic methods, and LDL cholesterol
was calculated using the Friedewald
equation. GHb was measured using high-
performance liquid chromatography.
Plasma CoQ10 was measured by reverse-
phase high-performance liquid chroma-
tography using electrochemical detection
(interassay coefﬁcient of variation 14%).
Plasma F2-isoprostane and 24-h urinary
20-hydroxyeicosatetraenoic acid levels
(markers of systemic oxidative stress)
were measured by gas chromatography-
mass spectrometry (interassay coefﬁcients
of variation 5.6 and 10%, respectively)
(6–8).
Data were analyzed using SPSS 15.0
(Chicago, IL) and SAS 9.1 (Cary, NC).
Plasma CoQ10 data (skewed distribution)
were logarithmically transformed for
parametric analysis. Treatment effects
were compared using mixed-effects mod-
els. Carryover effects were examined for
and excluded.
RESULTS— Participants were typi-
callymiddle-aged(meanSDage686
years) and overweight (BMI 29  4 kg/
m
2), with satisfactory control of glycemia
(GHb 6.9  0.7%), blood pressure (sys-
tolic 123  14 mmHg and diastolic 65 
7), and lipids (LDL cholesterol 1.8  0.3
mmol/l).Mediandurationofdiabeteswas
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history of stroke or coronary disease, and
26% had microvascular complications.
Eighty-threepercentofsubjectsweretak-
ing antihyperglycemic medication, most
commonly metformin (78%); 52% were
taking ACE inhibitors; 21% were taking
angiotensin receptor blockers; and 65%
were taking aspirin. Atorvastatin was the
most commonly prescribed statin (52%),
followed by simvastatin (35%) and prav-
astatin (13%).
Baseline brachial artery diameter was
similar at all assessments and unaltered by
CoQ10 supplementation (Table 1). CoQ10
increased brachial artery FMD by mean 
SEM1.00.5%(P0.04)comparedwith
placebo but did not alter nitrate-mediated
dilatation (P  0.66). Absolute percent
FMD pre- and postplacebo, pre- and post-
CoQ10, and change in percent FMD with
placebo and CoQ10 are shown in supple-
mental Figures A1, A2, and A3 (available in
an online appendix at http://care.diabetes
journals.org/cgi/content/full/dc08-1736/
DC1), re- spectively. Despite increasing
plasma CoQ10 levels 2.7-fold (P  0.001),
CoQ10 supplementation did not alter
plasma F2-isoprostane (P  0.58) or uri-
nary20-hydroxyeicosatetraenoicacidlevels
(P  0.28) or inﬂuence glycemia, blood
pressure, or lipids (P  0.05).
CONCLUSIONS — The new ﬁnding
was that CoQ10 supplementation im-
proved endothelial dysfunction in statin-
treated type 2 diabetic patients, with no
alteration in two markers of systemic ox-
idative stress. This is consistent with our
previous study in statin-naive dyslipide-
mic type 2 diabetic patients in whom
oral CoQ10 also improved brachial ar-
tery FMD but did not alter plasma F2-
isoprostane levels (4). However, a study
in coronary heart disease patients (20%
with diabetes and 80% statin-treated)
showed that oral CoQ10 increased both
brachial artery FMD and endothelium-
bound extracellular superoxide dis-
mutase activity, suggesting that the
beneﬁcial effects on endothelial function
are related to improvements in local vas-
cular oxidative stress (9). CoQ10 could
also decrease vascular oxidative stress by
recoupling endothelial nitric oxide syn-
thase and/or mitochondrial oxidative
phosphorylation.ThefactthatplasmaF2-
isoprostane levels in our diabetic subjects
werenotsigniﬁcantlydifferentfromthose
in our previously studied nondiabetic
control subjects (1,360  74 vs. 1,394 
122 pmol/l, respectively; P  0.80) (4)
probably reﬂects their satisfactory glyce-
mic control; our results might have dif-
fered had we included patients with
greater degrees of hyperglycemia and sys-
temic oxidative stress. Whether CoQ10
supplementation might improve endo-
thelial function by modulating other va-
soactive mediators, such as endothelin 1
(10) or asymmetric dimethylarginine,
(11) merits further investigation.
Our statin-treated subjects had lower
plasma CoQ10 concentrations compared
with those in the statin-naive dyslipide-
mic type 2 diabetic patients in our previ-
ous study (0.8 [0.2] vs. 1.3 [0.6] mol/l;
P  0.01) (4). Although the lowering of
plasma CoQ10 concentrations with prav-
astatin therapy was not shown to predict
cardiovascular outcomes in coronary pa-
tients (12), the effect of pravastatin (40
mg/day) on plasma CoQ10 levels was
modest (15% reduction vs. placebo)
andinhibitionofendogenousCoQ10pro-
duction may be greater with higher doses
of more potent statins (3).
Table 1—Effect of placebo and oral CoQ10 on arterial function, biochemical variables, and
blood pressure
Placebo Oral CoQ10 P
Baseline brachial artery diameter (mm)
Pretreatment 3.9  0.1 3.9  0.1
Treatment end 3.9  0.1 3.9  0.1
Change 0.1  0.0 0.0  0.0 0.69
Brachial artery FMD (%)
Pretreatment 2.2  0.6 2.2  0.7
Treatment end 2.1  0.7 3.2  0.5
Change 0.0  0.5 1.0  0.6 0.04
Brachial artery NMD (%)
Pretreatment 16.9  1.1 17.3  0.9
Treatment end 17.8  1.0 17.5  1.0
Change 0.9  0.9 0.2  0.8 0.66
Plasma CoQ10 (mol/l)
Pretreatment 0.9 (0.2) 0.8 (0.3)
Treatment end 0.8 (0.2) 2.2 (1.5)
Change 0.0 (0.1) 1.2 (1.5) 0.001
Plasma F2-isoprostanes (pmol/l)
Pretreatment 1,302  68 1,284  70
Treatment end 1,275  86 1,298  69
Change 27  55 14  42 0.58
Urinary 20-HETE (pmol/24 h)
Pretreatment 828  102 831  109
Treatment end 775  104 888  126
Change 53  80 57  117 0.28
GHb (%)
Pretreatment 7.0  0.1 7.0  0.2
Treatment end 6.9  0.2 7.0  0.2
Change 0.1  0.1 0.1  0.1 0.58
LDL cholesterol (mmol/l)
Pretreatment 1.9  0.1 1.7  0.1
Treatment end 1.9  0.1 2.0  0.1
Change 0.1  0.1 0.2  0.1 0.41
Systolic blood pressure (mmHg)
Pretreatment 126  4 122  3
Treatment end 121  3 121  4
Change 4  3 1  2 0.38
Diastolic blood pressure (mmHg)
Pretreatment 67  16 4  2
Treatment end 65  16 6  1
Change 2  11  1 0.09
Data are means  SEM or medians (interquartile range). Treatment effects compared using mixed-effects
models, with adjustment for baseline, treatment sequence, and period. 20-HETE, 20-hydroxyeicosatetra-
enoic acid; NMD, nitrate-mediated dilatation.
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thelial dysfunction despite satisfactory
control of blood pressure, glycemia, and
lipids and may be representative of the
proportionofstatin-treatedpatientsatin-
creased residual risk of cardiovascular
disease. Our absolute improvement in
FMD of 1% with CoQ10 supplementation
may potentially translate to a 10–25% re-
duction in residual cardiovascular risk in
these patients (13,14). Impaired FMD is a
consistent predictor of adverse cardiovas-
cular events. Several interventions that
improve FMD also improve cardiovascu-
lar outcomes (13–15). The signiﬁcance of
the ﬁndings in our report, however, re-
quires further investigation in a clinical
end point trial.
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